CSPIA
BBIO icon

Cary Street Partners Investment Advisory’s BridgeBio Pharma BBIO Stock Holding History

Cary Street Partners Investment Advisory’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35.6K Buy
478
+271
+131% +$19K 0.01% 621
2026
Q1 		$15.4K Sell
207
-360
-63% -$26.1K ﹤0.01% 615
2025
Q4 		$43.4K Buy
567
+508
+861% +$33.3K 0.01% 527
2025
Q3 		$3.06K Buy
59
+15
+34% +$732 ﹤0.01% 579
2025
Q2 		$1.9K Buy
44
+14
+47% +$509 ﹤0.01% 568
2025
Q1 		$1.04K Buy
+30
New +$1.01K ﹤0.01% 552

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Cary Street Partners Investment Advisory's BBIO Position: Q2 2026 in Review

Cary Street Partners Investment Advisory increased its BridgeBio Pharma (BBIO) stake by 131% in Q2 2026, buying an estimated $19K and bringing the position to 478 shares worth $35.6K. The position accounts for 0.01% of the portfolio, ranked #621.

Cary Street Partners Investment Advisory first reported a position in BBIO in Q1 2025 and has held it in 6 quarters since. The position peaked at $43.4K in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Cary Street Partners Investment Advisory held 478 shares of BridgeBio Pharma worth $35.6K as of Q2 2026.
  • Cary Street Partners Investment Advisory bought 271 BridgeBio Pharma shares in Q2 2026, an estimated $19K.
  • BridgeBio Pharma made up 0.01% of Cary Street Partners Investment Advisory's portfolio in Q2 2026, its #621 holding.
  • Cary Street Partners Investment Advisory first reported a position in BridgeBio Pharma in Q1 2025 and has held it in 6 quarters since.
  • Cary Street Partners Investment Advisory's BridgeBio Pharma position peaked at $43.4K in Q4 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Cary Street Partners Investment Advisory's 13F filing for Q2 2026, filed 17 Jul 2026.